MX359825B - Compuesto pirazol y su uso farmaceutico. - Google Patents
Compuesto pirazol y su uso farmaceutico.Info
- Publication number
- MX359825B MX359825B MX2014002552A MX2014002552A MX359825B MX 359825 B MX359825 B MX 359825B MX 2014002552 A MX2014002552 A MX 2014002552A MX 2014002552 A MX2014002552 A MX 2014002552A MX 359825 B MX359825 B MX 359825B
- Authority
- MX
- Mexico
- Prior art keywords
- medical purposes
- pyrazole compound
- formula
- pyrazole
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/10—Laxatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Abstract
Un compuesto de la siguiente Fórmula general [Ib]: (ver Fórmula) donde cada símbolo es el mismo como se definió en la descripción; o una de sus sales farmacéuticamente aceptables.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011188121 | 2011-08-31 | ||
US201161573433P | 2011-09-06 | 2011-09-06 | |
PCT/JP2012/072066 WO2013031922A1 (ja) | 2011-08-31 | 2012-08-30 | ピラゾール化合物及びその医薬用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2014002552A MX2014002552A (es) | 2014-04-25 |
MX359825B true MX359825B (es) | 2018-10-10 |
Family
ID=47756400
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2014002552A MX359825B (es) | 2011-08-31 | 2012-08-30 | Compuesto pirazol y su uso farmaceutico. |
Country Status (26)
Country | Link |
---|---|
US (5) | US8846746B2 (es) |
EP (3) | EP2784074A4 (es) |
JP (5) | JP6091811B2 (es) |
KR (1) | KR101989203B1 (es) |
CN (1) | CN103917535B (es) |
AR (2) | AR087701A1 (es) |
AU (1) | AU2012302723B2 (es) |
BR (1) | BR112014004651B1 (es) |
CA (1) | CA2845127C (es) |
CL (1) | CL2014000490A1 (es) |
CO (1) | CO6890098A2 (es) |
CY (1) | CY1121631T1 (es) |
DK (1) | DK3199533T3 (es) |
HK (1) | HK1202290A1 (es) |
IL (1) | IL230763A (es) |
MX (1) | MX359825B (es) |
MY (1) | MY172422A (es) |
PE (1) | PE20142343A1 (es) |
PL (1) | PL3199533T3 (es) |
RS (1) | RS58870B1 (es) |
RU (1) | RU2617678C2 (es) |
SG (1) | SG11201400244YA (es) |
SI (1) | SI3199533T1 (es) |
TW (1) | TWI549949B (es) |
WO (1) | WO2013031922A1 (es) |
ZA (1) | ZA201401071B (es) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR087701A1 (es) * | 2011-08-31 | 2014-04-09 | Japan Tobacco Inc | Derivados de pirazol con actividad inhibidora de sglt1 |
UA117092C2 (uk) | 2011-09-06 | 2018-06-25 | Байєр Інтеллектуал Проперті Гмбх | Амінозаміщені імідазопіридазини |
CA2872002C (en) | 2012-05-07 | 2019-01-15 | Masayuki Isaji | Pyrazole derivative and use thereof for medical purposes |
EP2920176B1 (en) | 2012-11-19 | 2017-09-13 | Bayer Pharma Aktiengesellschaft | Aminoimidazopyridazines as mknk1 kinase inhibitors |
US10022389B2 (en) * | 2013-02-04 | 2018-07-17 | Taisho Pharmaceutical Co., Ltd. | Prophylactic or therapeutic drug for constipation |
WO2014182955A2 (en) | 2013-05-08 | 2014-11-13 | The University Of Houston System | Targeting the egfr-sglt1 interaction for cancer therapy |
CN105294703B (zh) * | 2015-10-23 | 2018-01-23 | 西安近代化学研究所 | 3,7,10‑三氧代‑2,4,6,8,9,11‑六氮杂[3,3,3]螺桨烷的合成方法 |
BR112019002733A2 (pt) | 2016-08-11 | 2019-05-14 | Bayer Cropscience Ag | derivados de pirazolinil substituídos, processos para sua preparação e seu uso como herbicidas e/ou reguladores de crescimento da planta |
KR102467045B1 (ko) | 2016-08-15 | 2022-11-11 | 바이엘 크롭사이언스 악티엔게젤샤프트 | 3-아미노-1-(2,6-이치환 페닐)피라졸의 제조 방법 |
TWI805699B (zh) | 2018-03-01 | 2023-06-21 | 日商日本煙草產業股份有限公司 | 甲基內醯胺環化合物及其用途 |
PE20201068A1 (es) | 2018-04-04 | 2020-10-19 | Japan Tobacco Inc | Compuestos de pirazol sustituidos con heteroarilo y uso farmaceutico de los mismos |
CN114641314A (zh) * | 2019-09-04 | 2022-06-17 | 日本烟草产业株式会社 | 慢性肾脏病的治疗或预防方法 |
WO2021045159A1 (ja) | 2019-09-04 | 2021-03-11 | 日本たばこ産業株式会社 | 併用医薬による糖尿病の治療又は予防方法 |
US20230321044A1 (en) | 2020-03-19 | 2023-10-12 | Japan Tobacco Inc. | Treatment or prevention method for chronic heart failure |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2713225B1 (fr) | 1993-12-02 | 1996-03-01 | Sanofi Sa | N-pipéridino-3-pyrazolecarboxamide substitué. |
FR2692575B1 (fr) | 1992-06-23 | 1995-06-30 | Sanofi Elf | Nouveaux derives du pyrazole, procede pour leur preparation et compositions pharmaceutiques les contenant. |
US6387900B1 (en) * | 1999-08-12 | 2002-05-14 | Pharmacia & Upjohn S.P.A. | 3(5)-ureido-pyrazole derivatives process for their preparation and their use as antitumor agents |
EA005373B1 (ru) * | 1999-08-12 | 2005-02-24 | Фармация Италия С.П.А. | Производные 3(5)-аминопиразола, способ их получения и их применение в качестве противоопухолевых средств |
US8084467B2 (en) * | 1999-10-18 | 2011-12-27 | University Of Connecticut | Pyrazole derivatives as cannabinoid receptor antagonists |
ATE469161T1 (de) * | 2002-08-08 | 2010-06-15 | Kissei Pharmaceutical | Pyrazolderivat, dieses enthaltende medizinische zusammensetzung, medizinische verwendung davon, und zwischenprodukt für dessen herstellung |
JP2004137245A (ja) * | 2002-08-23 | 2004-05-13 | Kissei Pharmaceut Co Ltd | ピラゾール誘導体、それを含有する医薬組成物、その医薬用途及びその製造中間体 |
US7247628B2 (en) | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
DE102004028241B4 (de) | 2004-06-11 | 2007-09-13 | Sanofi-Aventis Deutschland Gmbh | Neue Fluorglykosidderivate von Pyrazolen, diese Verbindungen enthaltende Arzneimittel und Herstellung dieser Arzneimittel |
AR051446A1 (es) * | 2004-09-23 | 2007-01-17 | Bristol Myers Squibb Co | Glucosidos de c-arilo como inhibidores selectivos de transportadores de glucosa (sglt2) |
ES2328384T3 (es) | 2004-11-23 | 2009-11-12 | Warner-Lambert Company Llc | Derivados del acido 7-(2h-pirazol-3-il)-3,5-dihidroxi-heptanoico como inhibidores de hmg co-a reductasa para el tratamiento de la lipidemia. |
WO2007034279A2 (en) * | 2005-09-19 | 2007-03-29 | Pfizer Products Inc. | C3a antagonists and pharmaceutical compositions thereof |
JP5069894B2 (ja) | 2005-10-21 | 2012-11-07 | 田辺三菱製薬株式会社 | ピラゾール化合物 |
EP1951678A1 (en) | 2005-10-21 | 2008-08-06 | Mitsubishi Tanabe Pharma Corporation | Pyrazole compounds having cannabinoid receptor (cb1) antagonizing activity |
TWI378922B (en) * | 2005-10-21 | 2012-12-11 | Mitsubishi Tanabe Pharma Corp | A pyrazole compound |
US20070117858A1 (en) | 2005-11-23 | 2007-05-24 | Mingde Xia | Substituted 5-heteroaryl-1-phenyl-pyrazole cannabinoid modulators |
CL2007002904A1 (es) * | 2006-10-10 | 2008-06-06 | Amgen Inc Soc Organizada Bajo | Compuestos derivados de pirazolopirimidina; composicion farmaceutica; y uso para tratar una enfermedad seleccionada de diabetes, obesidad, asma y artritis entre otras. |
JP4994295B2 (ja) | 2007-04-20 | 2012-08-08 | 田辺三菱製薬株式会社 | 医薬組成物 |
WO2010048149A2 (en) | 2008-10-20 | 2010-04-29 | Kalypsys, Inc. | Heterocyclic modulators of gpr119 for treatment of disease |
JP2010222298A (ja) * | 2009-03-24 | 2010-10-07 | Shionogi & Co Ltd | Npyy5受容体拮抗作用を有するピロリドン誘導体 |
US8278302B2 (en) * | 2009-04-08 | 2012-10-02 | Boehringer Ingelheim International Gmbh | Substituted piperidines as CCR3 antagonists |
US8163704B2 (en) * | 2009-10-20 | 2012-04-24 | Novartis Ag | Glycoside derivatives and uses thereof |
CN110269856A (zh) | 2010-03-30 | 2019-09-24 | 维颂公司 | 多取代芳族化合物作为凝血酶的抑制剂 |
CA2804225C (en) | 2010-07-02 | 2018-05-01 | Aska Pharmaceutical Co., Ltd. | Heterocyclic compound and p27kip1 degradation inhibitor |
US20140018540A1 (en) | 2010-12-14 | 2014-01-16 | Electrophoretics Limited | Casein kinase 1delta (ck 1delta) inhibitors |
AR087701A1 (es) * | 2011-08-31 | 2014-04-09 | Japan Tobacco Inc | Derivados de pirazol con actividad inhibidora de sglt1 |
-
2012
- 2012-08-28 AR ARP120103173A patent/AR087701A1/es active IP Right Grant
- 2012-08-30 RU RU2014112048A patent/RU2617678C2/ru active
- 2012-08-30 KR KR1020147004780A patent/KR101989203B1/ko active IP Right Grant
- 2012-08-30 SI SI201231595T patent/SI3199533T1/sl unknown
- 2012-08-30 JP JP2012190429A patent/JP6091811B2/ja active Active
- 2012-08-30 DK DK17157922.0T patent/DK3199533T3/da active
- 2012-08-30 EP EP12827193.9A patent/EP2784074A4/en not_active Withdrawn
- 2012-08-30 AU AU2012302723A patent/AU2012302723B2/en active Active
- 2012-08-30 CN CN201280050398.9A patent/CN103917535B/zh active Active
- 2012-08-30 BR BR112014004651-4A patent/BR112014004651B1/pt active IP Right Grant
- 2012-08-30 SG SG11201400244YA patent/SG11201400244YA/en unknown
- 2012-08-30 TW TW101131507A patent/TWI549949B/zh active
- 2012-08-30 PL PL17157922T patent/PL3199533T3/pl unknown
- 2012-08-30 EP EP17157922.0A patent/EP3199533B1/en active Active
- 2012-08-30 PE PE2014001489A patent/PE20142343A1/es active IP Right Grant
- 2012-08-30 MX MX2014002552A patent/MX359825B/es active IP Right Grant
- 2012-08-30 MY MYPI2014000387A patent/MY172422A/en unknown
- 2012-08-30 WO PCT/JP2012/072066 patent/WO2013031922A1/ja active Application Filing
- 2012-08-30 US US13/599,665 patent/US8846746B2/en active Active
- 2012-08-30 EP EP19159289.8A patent/EP3524599A1/en active Pending
- 2012-08-30 CA CA2845127A patent/CA2845127C/en active Active
- 2012-08-30 RS RS20190581A patent/RS58870B1/sr unknown
-
2014
- 2014-02-02 IL IL230763A patent/IL230763A/en active IP Right Grant
- 2014-02-11 ZA ZA2014/01071A patent/ZA201401071B/en unknown
- 2014-02-25 CO CO14038962A patent/CO6890098A2/es active IP Right Grant
- 2014-02-27 CL CL2014000490A patent/CL2014000490A1/es unknown
- 2014-07-29 US US14/445,500 patent/US20150183763A1/en not_active Abandoned
-
2015
- 2015-03-17 HK HK15102725.1A patent/HK1202290A1/xx unknown
-
2017
- 2017-02-08 JP JP2017021326A patent/JP2017082005A/ja not_active Ceased
- 2017-12-21 US US15/850,874 patent/US20180346449A1/en not_active Abandoned
-
2018
- 2018-05-02 JP JP2018088578A patent/JP2018115216A/ja not_active Ceased
-
2019
- 2019-05-08 CY CY20191100491T patent/CY1121631T1/el unknown
- 2019-11-07 US US16/677,523 patent/US20200317644A1/en not_active Abandoned
-
2020
- 2020-05-01 JP JP2020081097A patent/JP2020125348A/ja not_active Ceased
-
2021
- 2021-09-06 AR ARP210102479A patent/AR123441A2/es unknown
-
2022
- 2022-12-02 US US18/061,309 patent/US20230348438A1/en active Pending
-
2023
- 2023-05-02 JP JP2023075967A patent/JP2023087032A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2014002552A (es) | Compuesto pirazol y su uso farmaceutico. | |
MX2013012542A (es) | Compuestos de amida y aplicacion farmaceutica para el mismo. | |
PH12015501993A1 (en) | Pyrazole-amide compound and medicinal uses therefor | |
PH12015501328A1 (en) | Meglumine salt of 6-flouro-3-hydroxy-2-pyrazine carboxamide | |
MX361499B (es) | Baricitinib deuterado. | |
MY184306A (en) | Compounds for the treatment and prophylaxis of respiratory syncytial virus disease | |
IN2015DN01035A (es) | ||
MX2015001246A (es) | Ibrutinib deuterado. | |
MY163187A (en) | Novel imidazo-oxazine compound or salt thereof | |
MY162411A (en) | Crystalline forms of a macrolide, and uses therefor | |
TW201144301A (en) | Processes for preparing linezolid | |
MX346248B (es) | Derivados de [1,2,3]triazol[4,5-d]pirimidina como agonistas de los agonistas del receptor canabinoide 2. | |
PH12015501088A1 (en) | Dimeric compounds | |
PH12015502178A1 (en) | Pyridinylpyrazoloquinoline compound | |
SA517381678B1 (ar) | مركبات داي هيدرو بيريميدين-2-أون واستخدامها الطبي | |
IN2012DN00765A (es) | ||
GB201101517D0 (en) | Receptor antagonists | |
GB201305247D0 (en) | Amide Compounds | |
IN2014DN10669A (es) | ||
MX342153B (es) | Compuestos para el tratamiento y profilaxis de enfermedad por el virus sincitial respiratorio. | |
GB2504042B (en) | Caspofungin or salts thereof with high purity, as well as preparation method and use thereof | |
MX2015015755A (es) | Derivados de perhidroquinoxalina utiles como analgesicos. | |
MX2012014796A (es) | Proceso para preparar 4-hidroxipiridinas. | |
GB201020397D0 (en) | Compounds | |
WO2011047530A8 (zh) | 类胡萝卜素衍生物及其制备方法和应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |